What question did this study set out to answer?

To evaluate a time-limited treatment strategy combining bendamustine/rituximab induction with venetoclax/rituximab consolidation for chronic lymphocytic leukemia.

June 6, 2026Hematological Oncology

Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi‐Center Study

View Full Paper

Ask AI

Bookmark

Authors

ALAndrew LipskyNewYork–Presbyterian Hospital BHBrian T. HillCleveland Clinic AWAllison WinterCleveland Clinic

Discussion

Member takes

Implication

Randomized trial shows effective disease control in CLL, indicating a potential shift in treatment strategy.

Key Points

To evaluate a time-limited treatment strategy combining bendamustine/rituximab induction with venetoclax/rituximab consolidation for chronic lymphocytic leukemia.
Multicenter, single-arm Phase 2 trial (NCT03609593)
Short-course induction with three cycles of bendamustine/rituximab followed by venetoclax ramp-up plus rituximab for six cycles
Total treatment duration of 15 months
Overall response rate (ORR) reached 86% with CR/CRi at 64% and PR at 21%
Among efficacy-evaluable patients, ORR was 100% with CR/CRi at 75%
Three-year progression-free survival (PFS) and overall survival (OS) were 87.5% and 92.7% respectively

Cite This Study

Lipsky et al. (2026) studied this question.

synapsesocial.com/papers/6a23bbeb71a5da9775e7753d https://doi.org/10.1002/hon.70205

View Full Paper

Ask AI

Bookmark

Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi‐Center Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi‐Center Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider